NCT06484530View on ClinicalTrials.gov

Gene-guided N-acetyl Cysteine for Prophylaxis of Anti-tuberculous Drug- Induced Hepatitis

PHASE4RecruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

March 12, 2024

Primary Completion Date

September 18, 2024

Study Completion Date

September 18, 2024

Conditions
Tuberculosis (TB)Isoniazid ToxicityRifampicin ToxicityPyrazinamide Adverse ReactionEthambutol ToxicityNAT2 Slow Acetylator StatusNAT2 Rapid Acetylator StatusNAT2 PolymorphismN-Acetylcysteine
Interventions
DRUG

N acetyl cysteine

1,200 mg/day for 8 weeks in NAT2 gene testing group and NAT2 gene phenotype is identified as slow acetylator.

Trial Locations (1)

10700

RECRUITING

Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok Noi

All Listed Sponsors
lead

Mahidol University

OTHER